



May 19, 2026

National Stock Exchange of India Limited,
Compliance Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400051,
Maharashtra, India

BSE Limited,
Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001,
Maharashtra, India

Dear Sir/Madam,

Subject : *Investor Presentation on Annual Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2026.*

Stock Code : *BSE – 539787, NSE – HCG*

Reference : *Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”).*

This is to inform that the Board of Directors of the Company, at their meeting held today i.e., May 19, 2026, *inter alia*, has approved the Annual Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2026 (“Financial Results”).

We enclose herewith the Investor Presentation on the Financial Results of the Company.

The above information is also available on the website of the Company and can be accessed at: <https://www.hcgoncology.com/>

You are requested to take the information on record.

Thanking You,

For HealthCare Global Enterprises Limited

Sunu Manuel
Company Secretary and Compliance Officer.
Encl: a/a



HEALTHCARE GLOBAL ENTERPRISES LIMITED



Q4 & FY26 Results Presentation

May 19, 2026



Safe Harbor



This presentation and its contents are confidential and are not for release, publication or distribution, in whole or in part, directly or indirectly, in or into or from the United States of America, Canada, Australia, Japan or any jurisdiction where such distribution is unlawful.

This presentation has been prepared by **HealthCare Global Enterprises Limited (the "Company")**. These materials are not for publication or distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). These materials are not an offer of securities for sale into the United States, Canada or Japan or any other jurisdiction. Any securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offering of any securities of the Company is being made in the United States.

The information contained in this presentation is for information purposes only and does not constitute or form part of an offer or invitation for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities, nor shall it or any part of it form the basis of or be relied on in connection with any contract, commitment or investment decision in relation thereto in India, the United States or any other jurisdiction.

No person accepts any liability whatsoever for any loss howsoever arising from the use of this document or of its contents or otherwise arising in connection therewith. The information set out herein may be subject to updating, completion, revision, verification and amendment without notice and such information may change materially. Financial information contained in this presentation has been derived from the restated consolidated and standalone financial statements of the Company and have been rounded off to the next integer, except percentages which have been rounded off to one decimal point.

This presentation contains certain "forward looking statements". Forward-looking statements are based on certain assumptions and expectations of future events. Actual future performance, outcomes and results may differ materially from those expressed in forward-looking statements as a result of a number of risks, uncertainties and assumptions. Although the Company believes that such forward-looking statements are based on reasonable assumptions, it can give no assurance that such expectations will be met. Neither the Company nor any of its advisors or representatives assumes any responsibility to update forward-looking statements or to adapt them to future events or developments.


This presentation includes certain industry data and projections that have been obtained from industry publications and surveys. Industry publications and surveys and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance that the information is accurate or complete. Neither the Company nor any of its advisors or representatives have independently verified any of the data from third-party sources or ascertained the underlying economic assumptions relied upon therein. No representation or claim is made that the results or projections contained in this presentation will actually be achieved. All industry data and projections contained in this presentation are based on data obtained from the sources cited and involve significant elements of subjective judgment and analysis, which may or may not be correct. For the reasons mentioned above, you should not rely in any way on any of the projections contained in this presentation for any purpose. No responsibility or liability whatsoever is undertaken for the contents hereof.

This presentation is based on information regarding the Company and the economic, regulatory, market and other conditions as in effect on the date hereof. It should be understood that subsequent developments may affect the information contained in this presentation, which neither the Company nor its advisors or representatives are under an obligation to update, revise or affirm.







Largest Pan-India Oncology Focused Hospital Chain



Our Presence




FY26 Operational and Financial Metrics



Note: (1) excludes Kenya and includes Chennai (2) Includes multispecialty; ~60 beds reclassified leading to an increase in number of beds; (3) Includes Chennai and MSR (4) Excludes fertility business (5) Adj. EBITDA is normalized for one-time cost of INR 39mn and ESOP of INR 14mn (6) RoCE is excluding fertility business and refers to pre – IND AS and post allocation of corporate cost



Proven Profitable Expansion Track Record



Note: (1) EBITDA mentioned above is adjusted for ESOP and other one-time costs (2) ~60 beds reclassified leading to an increase in number of beds



HCG Key Highlights: Q4 and FY26



HCG delivered revenue of INR 6,523 Mn in Q4FY26, reflecting ~11% YoY growth; FY26 revenue stood at INR 25,454 Mn, up ~15% YoY, supported by sustained volume growth and steady ARPP improvement

- Broad-based growth continued across clusters in Q4
 - West remained the key growth driver, growing ~13% YoY, supported by strong volume momentum across hospitals and improved traction
 - South delivered ~9% YoY growth, supported by healthy performance across tier-2 centres, partially offset by softer medical value tourism
 - East grew ~8% YoY, driven by higher patient volumes, with ARPP impacted by lower case-mix in Kolkata
- International business continued to scale meaningfully, growing ~39% YoY in Q4 FY26 and ~71% YoY in FY26, supported by ramp-up in radiation oncology, PET and stronger patient inflows
- FY26 performance remained strong across the network, with South, West and East clusters delivering ~13%, ~14% and ~11% YoY revenue growth, respectively. Excluding Milann, FY26 revenue grew ~15% YoY, driven by ~12% volume growth and ~3% ARPP improvement.
- Modality mix¹ (FY26): Medical oncology (~38% of revenue); Radiation (~14% of revenue); Surgical oncology (~21% of revenue); OP Onco services (~16% of revenue); Non-oncology specialties (~11% of revenue)
- Payor mix² (FY26): Cash + TPA (~56% of revenue); Govt (~33% of revenue); MVT(Medical Value Travel) (~2% of revenue) and others (~9% of revenue)

HCG delivered Adjusted EBITDA of INR 1,252 Mn in Q4FY26, up ~17% YoY; FY26 Adjusted EBITDA stood at INR 4,711 Mn, up ~19% YoY

- Adjusted EBITDA margin expanded to 19.2% in Q4 FY26 versus 18.3% in Q4 FY25, supported by operating leverage and improved network productivity
- FY26 Adjusted EBITDA margin expanded by ~68 bps YoY to 18.5%, reinforcing HCG's trajectory of sustainable margin improvement
- ROCE stood at 14.0% in FY26, supported by higher utilization, centre maturity and disciplined capital allocation

Key Business Developments: Strengthening platform for the next phase of growth

- North Bangalore facility commenced operations, bringing MR-LINAC technology to Bangalore and strengthening HCG's advanced oncology capabilities
- Rights issue completed to support growth investments and strengthen balance sheet
- Theranostics launch, robotic surgery expansion and addition of day care centre in Ahmedabad to further strengthen clinical capabilities, access and throughput
- Key roles hiring including CFO and investor relations have also been completed with leaders joining in May'26



Milann Divestment Update



- As part of its strategic objective to sharpen focus on its core oncology and allied healthcare businesses, HCG has agreed to exit non-core fertility business and divest 100% of its stake in BACC Healthcare Private Limited (operating under the Milann fertility brand), to Inviga Healthcare Fund I (managed by Inviga Investment Advisors Private Limited, an entity controlled by Dr. B.S. Ajaikumar, Promoter and Non-Executive Chairman of the Board)
- The proposed transaction is expected to enable HCG unlock value from a non-core investment and support more efficient deployment of capital toward expansion of oncology services
- The transaction values Milann at an enterprise valuation of INR 632 Mn. The equity consideration for 100% of the business (including certain transition services support) is INR 376 Mn⁽¹⁾ which shall be payable in two tranches:
 - 75% of the total consideration – i.e., INR 282 Mn shall be paid upfront upon consummation of the transaction; and
 - The remaining 25% – i.e., INR 94 Mn shall be payable within 18 months from the date of agreement
- The transaction is expected to close within Q1 FY27
- The proposed divestment will enhance long-term shareholder value through improved strategic alignment, stronger capital efficiency, and increased management focus on HCG's core oncology platform


Note 1: Net debt of INR 256mn including lease liabilities, debt like items and cash




Financial Highlights: Q4FY26




Overall Revenue




Adjusted Overall EBITDA¹




Adjusted PAT (Post - IND AS)²




Revenue (excl. Fertility)




Adjusted EBITDA (excl. Fertility)¹



Volumes³ (excl. Fertility)



ARPP (excl. Fertility)




Note:(1) Normalized for ESOP and one-time expenses (2) Q4FY26 PAT (post Non controlling interest) is normalized for one-time exceptional item pertaining to goodwill impairment (impact of ~INR 319mn); (3) # IP patients




Financial Highlights: FY26




Overall Revenue




Adjusted EBITDA¹




Adjusted PAT (Post - IND AS)²




ROCE³




Revenue (excl. Fertility)




Adjusted EBITDA (excl. Fertility)¹



Volumes (excl. Fertility)⁴





ARPP (excl. Fertility)



Note: (1) Normalized for ESOP and one-time expenses (2) FY26 PAT (post Non controlling interest) is normalized for one-time exceptional item pertaining to impact of new Labor code (INR 127mn, post effective tax impact of ~INR 100mn) and goodwill impairment (INR 319mn); (3) RoCE is excluding fertility business, and is pre - IND AS and post allocation of corporate cost; (4) # IP Patients




FY26 Revenue Mix: By Specialty and Payor



(1) OP services includes OPD consultation, diagnostics and pharmacy. (2) Payor mix excludes Fertility & International Business




Region-wise Performance Update: South




- Q4FY26 Highlights:**
- Delivered ~9% YoY revenue growth in Q4 FY26, supported by sustained momentum across key centres, particularly Vizag and Vijaywada.
 - Volumes grew 6% YoY during the quarter, reflecting steady patient traction across the cluster. This growth was achieved despite softer contribution from international patients
 - The cluster remains well-positioned for its next phase of growth, supported by the new North Bengaluru facility and the planned addition of ~25 beds at the Bangalore COE in FY27.


Overall Volumes



Overall ARPP




Revenue






Region-wise Performance Update: West




- Q4FY26 Highlights:**
- Continued and strong revenue growth momentum of ~13% YoY, supported by strong patient inflows across hospitals in Gujarat and Maharashtra
 - Volume growth of ~10% YoY driven by capacity expansion in Ahmedabad, new clinician additions and their ramp up
 - During Q4, Cash + TPA mix improved by 2% YoY


Overall Volumes



Overall ARPP




Revenue






Region-wise Performance Update: East




- Q4FY26 Highlights:**
- Delivered ~8% YoY revenue growth in Q4 FY26, supported by strong patient inflows and healthy traction across key centres, particularly Cuttack and Ranchi.
 - Volumes grew ~13% YoY during the quarter, reflecting continued momentum across the cluster and healthy underlying demand
 - ARPP moderated due to clinical transitions in Kolkata impacting case mix
 - The cluster remains well-positioned for FY27, supported by continued momentum in Cuttack and Ranchi, along with the expected onboarding of a new doctor team in Kolkata in Q1 FY27


Overall Volumes



Overall ARPP




Revenue






Region-wise Performance Update: International and Milann



- Q4 FY26 Highlights:**
- **Kenya Operations**
 - Revenue growth of 39% YoY, driven by continued and strong operating momentum and improving patient inflows and service mix
 - **Milann**
 - Divestment of Milann announced in May'26 and expected to close in Q1'FY27

International (Kenya)

Milann



Capital Expenditure (INR Mn)

Regions	FY25	FY26
South	1,221	1,804
West	802	794
East	133	140
International and Milann	41	147
Total	2,197	2,885

Net Debt (INR Mn)

Net Debt Items	31 st Mar 2026	31 st Mar 2025
Borrowings ⁽¹⁾	8,817	9,814
Less: Cash & Cash Equivalents ⁽²⁾	(5,430)	(3,497)
Net Debt	3,387	6,317
Capital Leases: Ind AS116	8,249	8,350
Net Debt (Incl. Leases)	11,636	14,667
<ul style="list-style-type: none"> During the quarter, we successfully completed our right issue to raise INR 4,250 Mn and the same was oversubscribed by 1.3x Deferred consideration for MG – Vizag of INR 1,543 Mn paid in Apr'26 		

Ongoing/ Planned Capex (INR Mn)

Sr. No	Particulars	Capex incurred till 31 st March 2026	Total Planned Capex	Bed Capacity	Expected Operational period
1	North Bangalore	1,000	1,290	110	Operational
2	Whitefield	137	Evaluating an alternate location		FY27

Given HCG's leadership position in Bangalore and increasing market attractiveness, we are evaluating an alternate location for our Whitefield hospital which would offer comprehensive cancer services

Additional brownfield expansion of 200+ beds planned in the next 24 months across Bangalore, Cuttack, Ranchi, Vizag and Bhavnagar


Note:

- Borrowings : Net of Bank balance held as margin money of ~INR 287mn as at 31st Mar 2026 and ~INR 208 Mn as at 31st Mar 2025.
- Cash and cash equivalents: Includes investment in mutual funds of ~INR 21mn as at 31st Mar 2026 and ~INR 21mn as at 31st Mar 2025



Net Debt (Pre Ind-AS)

HCG continues to demonstrate healthy cash conversion at 75% EBITDA to CFO; Balance sheet has further de-levered to ~1.43x following the rights issue and payment of Vizag acquisition, creating headroom to further invest in growth




Notes: (1) Net debt excluding lease liabilities (2) Including net interest income and other items comprising of both cash from investing and financing (3) Right issue proceeds is net off expenses



North Bangalore Update

North Bangalore Launch



- 1st in Bangalore market to offer MR-LINAC technology, creating a strong clinical and technology-led differentiation
- Spanning 1.5 lakh sq. ft. and strategically positioned to serve the rapidly growing northern corridor with catchment population of 2+ million⁽¹⁾
- Full-suite of offerings including medical, surgical, radiation oncology, nuclear medicine, PET-CT imaging and BMT unit
- Specialized programs in breast oncology, GI oncology, Thoracic oncology, and haemato-oncology



110
Installed Bed Capacity

2
1- MR-LINAC
1- Tomo

18
Full time Oncologists

5
Operating Theatres

1
PET-CT



Hospital Utilization and Growth Potential in Existing Centres

Existing network continue to witness healthy ramp up in utilization, with significant headroom for sustained future growth

Revenue
(INRmn)




9,950

11,330

2,830

25,454

FY26 Hospital Utilization (%)





Path to Improve Profitability and Return on Capital

- Continued movement of centres into higher revenue buckets driving structural improvement in HCG's EBITDA margins and ROCE
- The growing INR 50–100Mn cohort, with infrastructure already built out, provides a strong foundation for future margin expansion and progression into the >INR 100Mn category

Revenue Per Month	FY26		# of Centres ⁴		Like-for-Like Revenue Growth YoY
	EBITDA Margin ¹ (%)	ROCE ³ (%)	FY25	FY26	
>INR 100Mn (44% of revenue)	26% ¹	27%	3	4	13%
INR 50-100Mn (50% of revenue)	18% ¹	9%	12	14	17%
<INR 50Mn (6% of revenue)	5% ¹	(22)%	9	6	10%
Total (Excl Milann)	19%²	14%	25	25	

Notes: (1) Center-wise EBITDA margin is prior to corporate cost allocation (2) Consolidated EBITDA margin post corporate costs and excluding Milann (3) ROCE calculated as EBIT (Pre-IndAs, Post corporate cost allocation basis revenue) / Average net capital employed (4) KR road and DR centers in Bangalore are counted as one for the revenue bucketing, but separately counted for total



Q4 & FY26 Consolidated Profit & Loss Account



Profit and Loss (INR in Mn.)	Q4FY26	Q4FY25	Y-o-Y	FY26	FY25	Y-o-Y
Revenues from Operations	6,502.9	5,834.3		25,384.3	22,181.4	
Income from Govt. Grant	20.4	17.3		69.8	47.1	
Total Revenue from Operations	6,523.3	5,851.6	11%	25,454.1	22,228.5	15%
Cost of Goods Sold	1,767.1	1,540.3		6,923.0	5,806.0	
Employee Cost	924.7	914.9		3,771.6	3,469.4	
Medical Consultancy Charges	1,403.3	1,292.0		5,490.7	4,816.7	
Other Expenses	1,175.9	1,034.0		4,557.5	4,173.2	
Adjusted EBITDA	1,252.3	1,070.4	17%	4,711.3	3,963.2	19%
Adjusted EBITDA Margin (%)	19.2%	18.3%	+91 bps	18.5%	17.8%	+ 68 bps
One time cost	1.5	-		39.0	25.0	
ESOP's	-	13.2		14.4	65.4	
Reported EBITDA	1,250.8	1,057.2	18%	4,657.9	3,872.8	20%
Reported EBITDA Margin (%)	19.2%	18.1%	+111 bps	18.3%	17.4%	+88 bps
Depreciation	628.1	580.7		2,441.7	2,113.4	
Other Income	130.7	102.3		249.9	348.1	
EBIT	753.4	578.8		2,466.1	2,107.5	
Finance Cost	427.0	441.7		1,765.7	1,545.6	
Extraordinary Items	319.1	-		445.8	-	
Share in Profit/(loss) in JV and Associates	5.2	(0.9)		14.6	7.7	
Profit before Tax	12.5	136.2		269.2	569.6	
Taxes & Non controlling interest	9.2	(62.6)		(131.6)	(125.5)	
Profit After Tax	21.7	73.6		137.6	444.1	
PAT Margin (%)	0.3%	1.3%		0.5%	2.0%	
Adj. Profit After Tax⁽¹⁾	340.8	73.6		556.8	444.1	
Adj. PAT Margin (%)	5.2%	1.3%		2.2%	2.0%	
EPS (On reported PAT)	0.2	0.5		1.0	3.2	

Note: (1) FY26 PAT (post Non controlling interest) is normalized for one-time exceptional item pertaining to impact of new Labor code (INR 127mn, post effective tax impact of ~INR 100mn) and goodwill impairment of fertility business (INR 319mn)



Consolidated Balance Sheet



Balance Sheet – Equities & Liabilities (INR in Mn.)	Mar-26	Mar-25	Balance Sheet – Assets (INR in Mn.)	Mar-26	Mar-25
Equity share capital	1,493.0	1,394.2	Non-Current Assets		
Other equity	11,826.7	7,830.3	Property, Plant And Equipment	13,927.9	12,689.2
Equity attributable to owners of the Company	13,319.7	9,224.4	Capital Work in Progress	185.7	247.6
Non-controlling interests	782.4	676.1	Rights-of-use Assets	6,483.6	6,941.1
Total equity	14,102.1	9,900.5	Goodwill	3,875.9	4,299.5
Non-current liabilities			Other Intangible Assets	328.7	489.1
Financial liabilities			Financial Assets		
Borrowings	5,991.9	6,045.8	Investments	138.8	113.1
Lease liabilities	7,599.8	7,750.9	Other Financial Assets	823.9	704.7
Other financial liabilities	699.5	634.0	Deferred Tax Assets (Net)	399.2	249.9
Provisions	252.6	214.3	Income Tax Assets (Net)	1,074.2	855.4
Deferred tax liabilities (net)	23.4	35.4	Other Non-Current Assets	635.4	404.8
Other non-current liabilities	384.5	387.3	Total Non-Current Assets	27,873.3	26,994.4
Total non-current liabilities	14,951.7	15,067.7	Current Assets		
Current liabilities			Inventories	598.2	530.2
Financial Liabilities			Financial Assets		
Borrowings	3,112.2	3,976.5	Trade Receivables	4,207.0	4,009.0
Lease liabilities	649.7	599.0	Cash And Cash Equivalents	5,360.5	2,358.7
Trade payables	3,510.4	3,342.6	Bank Balances Other Than Cash And Cash equivalents	48.7	1,118.3
Other financial liabilities	1,896.7	1,959.2	Loans	33.6	27.0
Other current liabilities	388.4	367.0	Other Financial Assets	112.9	49.8
Provisions	233.8	193.5	Other Current Assets	324.1	345.0
Income tax liabilities (net)	36.0	26.4	Assets included in disposal group held for sale ⁽¹⁾	667.1	-
Liabilities included in disposal group held for sale ⁽¹⁾	344.4	-	Total Current Assets	11,352.0	8,438.0
Total Current Liabilities	10,171.5	10,464.2	Total Assets	39,225.3	35,432.4
Total Equity & Liabilities	39,225.3	35,432.4			

Note: (1) Assets and Liabilities of fertility business is classified as held for sale as at Mar'26



Cashflow Statement



Cashflow Statement (INR in Mn.)	Mar-26	Mar-25
Net Profit Before Tax	269.1	569.6
Adjustments For: Non - Cash Items / Other Investment Or Financial Items	3,945.6	3,685.2
Operating Profit Before Working Capital Changes	4,214.7	4,254.9
Changes in Working Capital	(425.7)	(765.0)
Cash generated from Operations	3,789.0	3,489.9
Direct Taxes Paid (Net of refund)	(318.2)	(318.8)
Net Cash from Operating activities	3,470.9	3,171.1
Net Cash from Investing activities	(1,774.7)	(4,877.5)
Net Cash from Financing activities	2,406.8	(424.4)
Net Increase/Decrease In Cash And Cash Equivalents	4,102.9	(2,130.8)
Add: Cash & Cash Equivalents At The Beginning Of The Period	(470.6)	1,660.2
Cash & Cash Equivalents At The End Of The Period	3,632.3	(470.6)


Closing cash reconciliation (INR in Mn.)	Mar-26	Mar-25
Closing cash as per Cashflow	3,632.3	(470.6)
Add: Bank Balances Other Than Cash And Cash equivalents	48.7	1,118.3
Add : Bank overdrafts repayable on demand	1,783.3	2,829.3
Less: Cash and cash equivalents classified as Assets included in disposal group held for sale	(55.1)	-
Closing Cash & Cash equivalents as per Balance Sheet	5,409.2	3,477.0

Note: Cashflow statement is including fertility business

HCG: India's Leading Oncology Platform



A Unique Oncology Platform Redefining Comprehensive Cancer Care Treatment



Underpinned by a personalized patient-centric approach, superior technology, and industry leading medical excellency

Note: (1) HCG in top 3 based on management estimates. (2) Excluding Chennai



HCG is Positioned as the 'Destination for Cancer Care' with Superior Clinical and Non-clinical Expertise...

Diagnostics

Treatment

Post Care




Genomics and Molecular diagnostics




Digital PET




Preventive Oncology




Medical Oncology and Haemato-Oncology



Radiation Oncology



Surgical Oncology




Molecular Imaging and Theranostics



Psychological support



Preventive Oncology



Physical Examination




Laboratory Tests



Home Health Services




Digital Pathology



Digital PET




Preventive Oncology



Genomics




CTC¹ detection




Chemotherapy




Radiation



Robotic Surgery




Actinium and Lutetium therapy




Immunotherapy




Psycho-oncology




Liver Transplant




Iodine Therapy




Targeted Drug Therapy




Pediatric Oncology




Organ preservation & Reconstructive surgery




Endocrine Therapy




Patient Care




Home Health Services



Psychological Support




Preventive Oncology



Nutrition



Rehab




Genetic Counselling



...including Cutting-edge Technology


TRACK RECORD OF BEING 1st TO LAUNCH ADVANCED TECHNOLOGY IN INDIA




Introducing organ-specific working committees – gastrointestinal, head & neck, breast, etc. for better data collection & analysis to improve patient outcome

State-of-the-art Equipment in each modality


DIAGNOSTICS




Digital PET




Digital CT Pathology




Automated Breast Volume Scanner



Digital Mammography




Skyra Tesla 3T for MRI




Molecular / Genomics Lab

Total PET CTs : 19


RADIOTHERAPY




Cyber Knife




MR-LINAC




True Beam



Versa HD




Radixact




Tomotherapy

Total LINACs : 38


MEDICAL/SURGICAL ONCOLOGY




Da Vinci Robot



Versius Robot



Holo Lens



Bone Marrow Transplant Units

Total Robots: 9

Note:(1) In new North Bangalore facility



Clinical Outcomes, Growth and Profitability

A Optimize Existing Network	B Invest in Growth	C Improve Network Efficiency	D Enhance Patient Experience
1. Build best-in-class talent → improve case mix	1. Brownfield expansion across key hospitals	1. Undertake prudent cost optimization initiatives	1. Invest in upgrading existing infrastructure
2. Focused marketing efforts to become provider of choice across payor types	2. Strengthen presence in existing markets	2. Focus on operating leverage to improve margins	2. Maintain leadership in medical technology
3. Scale up international business	3. Enter identified and attractive markets which fit the expansion framework	3. Develop asset light adjacencies – Day care, Diagnostics etc.	3. Leverage digital & tech to improve patient experience

Prudent Capital Allocation



CIN: L15200KA1998PLC023489

About Us: HealthCare Global Enterprises Ltd. (HCG), headquartered in Bengaluru, is the largest provider of cancer care in India. Through its network of 25 hospitals across India and Africa, HCG has brought advanced cancer care to the doorstep of millions of people. HCG's comprehensive cancer centers provide expertise and advanced technologies for the effective diagnosis and treatment of cancer under one roof.

For updates and specific queries, please visit www.hcgoncology.com or contact:

HealthCare Global Enterprises Limited
investors@hcgoncology.com

Mr. Anoop Poojari / Mr. Suraj Digawalekar
CDR India
anoop@cdr-india.com / suraj@cdr-india.com
Tel: +91 98330 90434 / +91 98211 94418



THANK YOU
